Brii Biosciences Limited Stock Performance
| BRIBF Stock | USD 0.30 0.00 0.00% |
Brii Biosciences holds a performance score of 10 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 2.17, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Brii Biosciences will likely underperform. Use Brii Biosciences information ratio, as well as the relationship between the skewness and day median price , to analyze future returns on Brii Biosciences.
Risk-Adjusted Performance
OK
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Brii Biosciences Limited are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite nearly weak fundamental drivers, Brii Biosciences reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 1 B | |
| Total Cashflows From Investing Activities | -475.8 M |
Brii |
Brii Biosciences Relative Risk vs. Return Landscape
If you would invest 13.00 in Brii Biosciences Limited on December 25, 2024 and sell it today you would earn a total of 17.00 from holding Brii Biosciences Limited or generate 130.77% return on investment over 90 days. Brii Biosciences Limited is currently producing 2.2164% returns and takes up 17.0247% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Brii, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Brii Biosciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Brii Biosciences' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Brii Biosciences Limited, and traders can use it to determine the average amount a Brii Biosciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1302
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | BRIBF | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 17.02 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.22 actual daily | 44 56% of assets have higher returns |
Risk-Adjusted Return
| 0.13 actual daily | 10 90% of assets perform better |
Based on monthly moving average Brii Biosciences is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Brii Biosciences by adding it to a well-diversified portfolio.
Brii Biosciences Fundamentals Growth
Brii Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Brii Biosciences, and Brii Biosciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Brii Pink Sheet performance.
| Return On Equity | -5.34 | |||
| Return On Asset | -0.19 | |||
| Operating Margin | (10.33) % | |||
| Current Valuation | 305.78 M | |||
| Shares Outstanding | 723.35 M | |||
| Price To Book | 0.95 X | |||
| Price To Sales | 10.64 X | |||
| EBITDA | (4.18 B) | |||
| Cash And Equivalents | 3.22 B | |||
| Cash Per Share | 4.45 X | |||
| Total Debt | 17.47 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | 4.43 X | |||
| Cash Flow From Operations | (879.46 M) | |||
| Earnings Per Share | (1.42) X | |||
| Total Asset | 3.61 B | |||
About Brii Biosciences Performance
By analyzing Brii Biosciences' fundamental ratios, stakeholders can gain valuable insights into Brii Biosciences' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Brii Biosciences has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Brii Biosciences has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. The company was incorporated in 2017 and is based in Beijing, China. Brii Bioscience is traded on OTC Exchange in the United States.Things to note about Brii Biosciences performance evaluation
Checking the ongoing alerts about Brii Biosciences for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Brii Biosciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Brii Biosciences is way too risky over 90 days horizon | |
| Brii Biosciences has some characteristics of a very speculative penny stock | |
| Brii Biosciences appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (4.16 B) with profit before overhead, payroll, taxes, and interest of 92.54 M. | |
| Brii Biosciences Limited has accumulated about 3.22 B in cash with (879.46 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.45, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Brii Biosciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Brii Biosciences' stock is overvalued or undervalued compared to its peers.
- Examining Brii Biosciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Brii Biosciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Brii Biosciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Brii Biosciences' pink sheet. These opinions can provide insight into Brii Biosciences' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Brii Pink Sheet analysis
When running Brii Biosciences' price analysis, check to measure Brii Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Brii Biosciences is operating at the current time. Most of Brii Biosciences' value examination focuses on studying past and present price action to predict the probability of Brii Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Brii Biosciences' price. Additionally, you may evaluate how the addition of Brii Biosciences to your portfolios can decrease your overall portfolio volatility.
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Stocks Directory Find actively traded stocks across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes |